These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 24806479)

  • 1. Hybrid modeling for quality by design and PAT-benefits and challenges of applications in biopharmaceutical industry.
    von Stosch M; Davy S; Francois K; Galvanauskas V; Hamelink JM; Luebbert A; Mayer M; Oliveira R; O'Kennedy R; Rice P; Glassey J
    Biotechnol J; 2014 Jun; 9(6):719-26. PubMed ID: 24806479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Process analytical technology (PAT) for biopharmaceutical products.
    Rathore AS; Bhambure R; Ghare V
    Anal Bioanal Chem; 2010 Sep; 398(1):137-54. PubMed ID: 20480150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality-by-design for biotechnology-related pharmaceuticals.
    Mandenius CF; Graumann K; Schultz TW; Premstaller A; Olsson IM; Petiot E; Clemens C; Welin M
    Biotechnol J; 2009 May; 4(5):600-9. PubMed ID: 19418475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multivariate PAT solutions for biopharmaceutical cultivation: current progress and limitations.
    Mercier SM; Diepenbroek B; Wijffels RH; Streefland M
    Trends Biotechnol; 2014 Jun; 32(6):329-36. PubMed ID: 24732022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How can measurement, monitoring, modeling and control advance cell culture in industrial biotechnology?
    Carrondo MJ; Alves PM; Carinhas N; Glassey J; Hesse F; Merten OW; Micheletti M; Noll T; Oliveira R; Reichl U; Staby A; Teixeira AP; Weichert H; Mandenius CF
    Biotechnol J; 2012 Dec; 7(12):1522-9. PubMed ID: 22949408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Process analytical technology (PAT) for biopharmaceutical products: Part II. Concepts and applications.
    Read EK; Shah RB; Riley BS; Park JT; Brorson KA; Rathore AS
    Biotechnol Bioeng; 2010 Feb; 105(2):285-95. PubMed ID: 19731253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and establishment of specifications for biopharmaceuticals.
    Davis GC; Riggin RM
    Dev Biol Stand; 1997; 91():49-54. PubMed ID: 9413683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specifications from a biotechnology industry perspective.
    Garnick RL
    Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-process testing and limits.
    Sjöholm I
    Dev Biol Stand; 1997; 91():73-8. PubMed ID: 9413685
    [No Abstract]   [Full Text] [Related]  

  • 10. Strategic funding priorities in the pharmaceutical sciences allied to Quality by Design (QbD) and Process Analytical Technology (PAT).
    Aksu B; De Beer T; Folestad S; Ketolainen J; Lindén H; Lopes JA; de Matas M; Oostra W; Rantanen J; Weimer M
    Eur J Pharm Sci; 2012 Sep; 47(2):402-5. PubMed ID: 22749874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioprocessing in the Digital Age: The Role of Process Models.
    Narayanan H; Luna MF; von Stosch M; Cruz Bournazou MN; Polotti G; Morbidelli M; Butté A; Sokolov M
    Biotechnol J; 2020 Jan; 15(1):e1900172. PubMed ID: 31486583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
    Garcia FA; Vandiver MW
    PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of specifications for biotechnology products--perspective from Europe.
    Trouvin JH
    Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679
    [No Abstract]   [Full Text] [Related]  

  • 14. A united front.
    Nature; 2011 Apr; 472(7344):389-90. PubMed ID: 21525888
    [No Abstract]   [Full Text] [Related]  

  • 15. Raw material considerations.
    Lubiniecki AS; Shadle PJ
    Dev Biol Stand; 1997; 91():65-72. PubMed ID: 9413684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A special report on India's biotech scenario: advancement in biopharmaceutical and health care sectors.
    Chakraborty C; Agoramoorthy G
    Biotechnol Adv; 2010; 28(1):1-6. PubMed ID: 19931371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunities and challenges of real-time release testing in biopharmaceutical manufacturing.
    Jiang M; Severson KA; Love JC; Madden H; Swann P; Zang L; Braatz RD
    Biotechnol Bioeng; 2017 Nov; 114(11):2445-2456. PubMed ID: 28710854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global perspective on specifications for biotechnology products--perspective from Japan.
    Hayakawa T
    Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of Knowledge Management in Development and Lifecycle Management of Biopharmaceuticals.
    Rathore AS; Garcia-Aponte OF; Golabgir A; Vallejo-Diaz BM; Herwig C
    Pharm Res; 2017 Feb; 34(2):243-256. PubMed ID: 27785590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Process analytical technology (PAT) for biopharmaceutical products: Part I. concepts and applications.
    Read EK; Park JT; Shah RB; Riley BS; Brorson KA; Rathore AS
    Biotechnol Bioeng; 2010 Feb; 105(2):276-84. PubMed ID: 19731252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.